SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- "Heritage meets digital technology, Shinsegae paves its way to become an iconic landmark of Seoul, alluring customers from all around the world."
Twinkling lights and glamorous moving images on the screen, Shinsegae Department Store, Korea's first department store since 1963, presents a new landmark of Seoul in Myeong-dong which is located in the center of the capital and brings in the highest population of tourists.
Shinsegae Department Store has been an absolute favourite amongst millions of global customers along with Harrods(UK) and Isetan(Japan), taking the chart of No.1 leading position in the Korean department store industry by far.
Last year, Shinsegae Department Store in Myeong-dong has been visited by over 6 million customers from different countries, making the spot a 'must-visit-place' for Christmas season.
For the past 10 years, Shinsegae has delivered hopes and excitements to its onlookers visiting the place, wishing the best Christmas and New Year's Eve for everyone.
With a size of three basketball courts(1292.3㎡), Shinsegae's mega-sized digital signage is now recreated as 'Shinsegae Square' and presents an overwhelming beauty with the visuals from the screen.
This year, Shinsegae is showcasing a short film called 'Pursuit of Christmas Moments' to give the experience of joy and magical moments to the audience, elevating thrills for Christmas and New Year's Eve.
The film depicts a story of Shinsegae Department Store being transformed into a magical Christmas castle along with fancy dinner parties inside and amusement parks embellished with glittering lights in the night sky, which will leave unforgettable memories for the visitors.
On the 31st of December, Shinsegae Square district will be presented as the spot to celebrate New Year's Eve as it will exhibit diverse K-culture contents and media artworks.
Harmoniously permeated with historical buildings nearby, the audience will be fascinated by magnificent and breath-taking sceneries with feasts of colorful lights that Shinsegae Square sheds.
"Shinsegae Department Store now presents 'Shinsegae Square' where visual beauty and cutting-edge technologies are met to make the most cherishable memories to those visiting Seoul," Shinsegae said.
"Rebranded as the iconic cultural hub with its K-culture contents and media artworks, Shinsegae Square will proceed to become the ultimate 'lifestyle destination', nowhere to be compared in Seoul."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Shinsegae spreads Christmas magic to the world with a new global landmark 'Shinsegae Square'
Shinsegae spreads Christmas magic to the world with a new global landmark 'Shinsegae Square'
Shinsegae spreads Christmas magic to the world with a new global landmark 'Shinsegae Square'
Shinsegae spreads Christmas magic to the world with a new global landmark 'Shinsegae Square'
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across
North America, Asia, Europe and the Middle East
NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.
The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment.
In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed."
CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed."
Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
Investors:
Mike Feher
mike.feher@cath.works
Media:
Sarita Monico
sarita.monico@cath.works
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
